Michael G. Fradley, MD: How Does Atrial Fibrillation Affect Outcomes and Health-Care Utilization Among Patients With CLL?
ASCO 2026
Michael G. Fradley, MD, of the University of Pennsylvania School of Medicine, discusses findings from a study which evaluated impact of atrial fibrillation on cardiovascular outcomes (stroke, bleeding, heart failure) and health-care utilization in patients with chronic lymphocytic leukemia (CLL) overall, by age, and by treatment (Abstract 7042).
The ASCO Post Staff
Atish Choudhury, MD, PhD, of Dana-Farber Cancer Institute, talks about findings from the phase II A-DREAM/Alliance A032101 trial, which explored the possibility of androgen-deprivation (ADT) interruption in patients with metastatic hormone-sensitive prostate cancer who had an exceptional response to androgen receptor pathway inhibitors (ARPIs) (Abstract 5004).
Elizabeth Smyth, MD, of Oxford NIHR Biomedical Research Centre, Churchill Hospital, discusses three major studies presented at this year’s meeting: the antibody-drug conjugate izalontamab brengitecan in recurrent or metasatic esophageal squamous cell carcinoma (Abstract 4008); the ATTRACTION-6 study of chemoimmunotherapy in HER2-negative advanced gastric/gastroesophageal junction (GEJ) cancer (Abstract 4006); and an investigational EP4 antagonist in combination with chemoimmunotherapy as a first-line strategy for HER2-negative gastric/GEJ cancer (Abstract 4007).
The ASCO Post Staff
Mali Barbi, MD, MS, of Northwell Health Cancer Institute Center for Women's Cancer, discusses durable survival benefits shown in the NRG-GY018 trial with pembrolizumab and the RUBY trial with dostarlimab for patients with mismatch repair–deficient (dMMR) endometrial cancer. In addition, B7-H4 antibody-drug conjugates such as puxitatug samrotecan are emerging as options for relapsed/metastatic disease.
The ASCO Post Staff
Kevin Kalinsky, MD, MS, FASCO, of Winship Cancer Institute of Emory University, provides an update focusing on progression-free survival after next line of treatment and subsequent therapies among patients enrolled in the ASCENT-04 trial. The study compared sacituzumab govitecan plus pembrolizumab vs chemotherapy plus pembrolizumab in patients with previously untreated PD-L1–positive metastatic triple-negative breast cancer (Abstract LBA1000).
Joel W. Neal, MD, PhD, of Stanford Cancer Institute, discusses updated overall survival data from cohort C of the CHRYSALIS-2 trial, which looked at first-line amivantamab plus lazertinib in previously untreated patients with atypical EGFR-mutated advanced non–small cell lung cancer (NSCLC) (Abstract 8501).
